Adjunct Industries

Global PR agency with documented agency-of-record work for Filament Health in the psychedelic therapeutics ecosystem.

Canada-based legal and consulting practice advising regulated-industry clients on psychedelic access, controlled-substance pathways, constitutional/regulatory issues, and policy-facing market development.

Canadian business law firm with published advisory work on legal and regulatory frameworks for psychedelics companies, including public-market and disclosure implications under Canadian law.

Brand strategy and identity agency with documented psychedelic-sector work, including positioning and identity development for Field Trip.

US-based economic consulting firm with published outcomes and cost-effectiveness analyses on esketamine treatment pathways relevant to payer decision-making and market access strategy.

Law firm providing psychedelic-sector legal counsel across DEA/FDA pathway navigation, transactional support, and healthcare-compliance risk management for clinics, facilitators, and research organizations.

Consultant Agency for Psychedelic Services (CAPS) is a UK-based advisory practice led by Dr Ben Sessa, providing consultancy for individuals, clinics, companies, and investors developing psychedelic and medical-cannabis services.

Swedish full-service CRO with early-phase concentration, integrated site network, and in-house capabilities spanning project management, monitoring, biometrics, pharmacovigilance, and medical writing.

Specialist communications firm focused on neuropsychiatry, mental health, and psychedelics, with public partner/client logos across research, biotech, and nonprofit stakeholders.

Regulatory and scientific consulting provider for psychedelic businesses and research teams, with operational compliance support for licensing, security, SOP design, and controlled-substance workflows.

Economic and strategy consultancy with life sciences advisory services, including published analysis on the evolving psychedelic therapeutics landscape and market implications.

Clinilabs Drug Development Corporation is the only global full-service contract research organisation (CRO) exclusively focused on central nervous system drug development, with over 25 years of experience managing Phase 1–3 trials across psychiatric, neurological, and substance-use disorders. It partnered with Cybin to conduct the first-in-human Phase 1/2a trial of CYB003, a deuterated psilocybin analog for major depressive disorder, obtaining DEA Schedule I licensing to support this psychedelic study.

Psychedelic and psilocybin-focused legal practice supporting operators and organizations with regulatory navigation, compliance strategy, and legal risk mitigation in emerging plant-medicine markets.

International regulatory affairs consultancy (UK/EU/US footprint) supporting life-science organizations across development to post-licensing, including dedicated analysis of psychedelic-drug regulatory pathways.

Brazil-based law firm with a leading IP and life-sciences practice, contributing legal and regulatory analysis on psychedelic medicines in Brazil and advising on IP-protection strategy in regulated sectors.

Delphi is a psychedelic healthcare consultancy focused on responsible integration into mainstream care. Led by Lia Mix and a cross-sector team, Delphi supports healthcare providers, investors, government agencies, and psychedelic organisations with strategy, education, and implementation guidance across regulation, delivery, and reimbursement. A major Delphi initiative is IHPI (Ibogaine Healthcare Policy Institute), a neutral, evidence-based, implementation-focused institute that develops coverage playbooks, health-economics models, and delivery blueprints for safe ibogaine adoption. Delphi also leads HOPE (Health Outcomes and Psychedelic Economics), a collaborative effort to generate independent economic evidence that can inform payer policy and broader healthcare access decisions.

Experience and interior-design studio linked via syndicated Novamind disclosures to psychedelic-clinic concept development.

US pharmacovigilance and drug-safety specialist providing adverse-event reporting, medical monitoring, and compliance operations for biotech and pharmaceutical sponsors, including psychedelic clinical programs.

US public-relations and marketing agency with a dedicated psychedelics-focused practice and messaging for regulated neuro-wellness brands.

Global architecture and design firm with documented psychedelic-care environment work, including the Bill Richards Center for Healing.

Integrated creative studio with documented project work for Numinus, spanning brand and digital expression for a psychedelic healthcare stakeholder.

Canadian brand strategist and designer with published wellness and psychedelic-therapy adjacent case work.

Toronto-based boutique law firm operating a dedicated psychedelic law practice, advising individuals and organizations on regulatory compliance, governance, contracts, and legal risk in Canada’s psychedelic sector.

National law firm with a dedicated psychedelics and emerging therapies legal practice supporting organizations operating in complex U.S. therapeutic, regulatory, and commercialization pathways.

Commercial real-world data products and linked evidence assets used in life sciences research and regulatory support.

Care-delivery platform for ketamine-assisted psychotherapy enabling licensed therapists to deliver KAP through a coordinated technology and prescriber network model.

Strategic communications and investor-relations firm with documented client mandates in the clinical psychedelics sector.

International branding and digital experience agency with published psychedelic mental-health branding work for Klarisana.

Neurotechnology company developing non-invasive brain measurement systems with applications in psychiatry and published psychedelic-adjacent ketamine research collaborations.

Global strategy consultancy with US/EU healthcare practices and published analysis on psychedelic treatment pathways, funding dynamics, and commercialization implications.

Canadian law firm with a dedicated cannabis-and-psychedelics regulatory practice advising on Section 56 pathways, Special Access Program matters, licensing compliance, and controlled-substance legal strategy.

Global commercialization and market access advisory firm with published commentary on positioning psychedelic medicines within biopharmaceutical development frameworks.

UK law firm with a dedicated psychoactive medicines practice providing regulatory, commercial, and IP counsel for psychedelic and cannabis organizations across research, clinic, and supply-chain contexts.

Ketamine therapy platform combining telehealth, digital treatment flow, and app-guided support for depression and related mental health conditions.

Clinical-stage AI neuroengineering platform company focused on designing psychoactive effect profiles and developing next-generation neuropsychiatric programs with psychedelic relevance.

Psychedelic-focused digital platform supporting protocolized care operations, patient journey tracking, and program management for providers and organizations.

PR and digital-communications agency with dedicated psychedelics-focused public-relations and content services for companies and nonprofits.

Digital ketamine treatment platform offering app-enabled preparation, guided sessions, and integration support for mental health care.

Psychiatry technology and real-world evidence platform supporting interventional mental health care, including psychedelic-assisted therapy workflows and psilocybin outcomes initiatives.

Boutique creative studio explicitly focused on modern psychedelic branding, immersive/experiential design, and science-forward communications aesthetics.

US psychedelic drug-development consultancy providing clinical trial roadmaps, regulatory planning, and operational integration frameworks for emerging neuropsychiatry programs.

Nonprofit psychedelic prior-art and patent-analysis organization that supports patent quality, prior-art discovery, and intellectual-property transparency for innovators, examiners, and the public.

UK-based psychedelic-focused consultancy offering strategic and business development services, education curriculum design, and partner collaborations for organizations in the sector.

US-based cannabis and psychedelic consulting firm providing licensing, compliance, SOP, and operational support alongside strategic planning for psychedelic ventures.

Psychedelic integration and advisory practice offering preparation/integration support and explicit psychedelic business consulting and coaching for practitioners and service builders.

Psychedelic intelligence platform that combines industry reporting with advisory and consultancy services for investors and operators, including strategic support and talent search.

US-based consultancy supporting hospitals and clinics with psychedelic and ketamine service implementation, including strategic planning, staffing, protocol setup, and quality systems.

Boutique digital and creative agency with case-study evidence for ketamine-clinic growth campaigns and conversion-focused patient acquisition work.

Independent creative studio focused on brand identity, packaging, and web design, with documented project work for Psychedelic Water.

Canadian interior and experience design studio with documented psychedelic-assisted care environment work (SABI Mind clinic in Calgary).

Independent creative agency providing brand strategy, visual identity, and digital design for wellness and psychedelic-oriented organizations.

Toronto law firm focused on psychedelics and controlled-substance legal operations, supporting licensing strategy, Health Canada interactions, audit/inspection readiness, and compliance architecture across research-to-commercial pathways.

Psychedelic-focused consulting practice led by Scott Gagel, PA-C, offering clinically informed guidance, assessment, and consultation services for individuals exploring plant-medicine treatment pathways.

Target Health Inc. is a New York-based full-service contract research organization (CRO) and clinical trials software company. Known for its proprietary electronic data capture system and a 100% success rate on FDA market applications, it provides regulatory affairs, clinical research management, biostatistics, and paperless trial platform services to pharmaceutical and biotech sponsors.

Psychedelic-focused law firm advising clinics, researchers, nonprofit organizations, and religious groups on controlled-substance licensing, compliance strategy, and policy-facing legal frameworks.

An independent clinical research organization (CRO) founded in 1977 and headquartered in Rockville, Maryland, specializing in the design and management of clinical trials. Emmes has expertise across therapeutic areas including ophthalmology, neurology, and immunology, providing biostatistics, data management, and regulatory support for academic and government-sponsored trials.

Purpose-led healthcare consultancy focused on integrating psychedelic-assisted therapy into health systems, with explicit services across strategic planning, implementation, reimbursement, and go-to-market execution.

Law firm focused on cannabis and psychedelics law, with advisory work spanning FDA/DEA pathways, controlled-substance compliance, and policy implementation in emerging psychedelic regulatory programs.

Psilocybin-focused organization with integration and program infrastructure, including digital and genomics-oriented support claims around therapeutic deployment.

Adaptive digital music platform for psychedelic and consciousness-altering therapy contexts, enabling immersive, session-responsive media experiences.

Miami-based boutique consulting firm supporting cannabis and psychedelic organizations with product strategy, operational optimization, and capability development.

Global full-service CRO with a dedicated psychedelic center of excellence supporting psychiatry-focused psychedelic clinical development programs, including large multicountry studies.